Logo

New Products: LifeCodexx's PrenaTest

Jul 10, 2013
Premium

GATC Biotech subsidiary LifeCodexx has updated its noninvasive sequencing-based PrenaTest for fetal trisomies so that it can be performed in high-risk pregnancies as early as nine weeks. The company incorporated a technology dubbed QuantYfeX, which it uses to measure the amount of cell-free fetal DNA in the mother's blood. The PrenaTest can be performed when cffDNA is above 4 percent.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Next-Generation Sequencing
LifeCodexx
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.